Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.

Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J.

Hum Pathol. 2009 Feb;40(2):252-8. doi: 10.1016/j.humpath.2008.07.014. Epub 2008 Oct 5.

PMID:
18835619
2.

Rare prostatic carcinomas: histogenesis and morphologic pattern.

Losi L, Brausi M, Di Gregorio C.

Pathologica. 1994 Aug;86(4):366-70. Review.

PMID:
7708435
3.
4.
5.

Neuroendocrine differentiation in prostatic malignancy.

di Sant'Agnese PA, Cockett AT.

Cancer. 1996 Jul 15;78(2):357-61. Review.

PMID:
8674017
6.

Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.

Priemer DS, Montironi R, Wang L, Williamson SR, Lopez-Beltran A, Cheng L.

Endocr Pathol. 2016 Jun;27(2):123-35. doi: 10.1007/s12022-016-9421-z. Review.

PMID:
26885643
7.

Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.

Cussenot O, Villette JM, Cochand-Priollet B, Berthon P.

Prostate Suppl. 1998;8:43-51. Review.

PMID:
9690663
8.

[Management of neuroendocrine prostate carcinoma: Literature review].

Yossi S, Brahmi T, Enachescu C, Selmaji I, Lapierre A, Samlali H, Chapet O.

Cancer Radiother. 2016 Jun;20(4):330-5. doi: 10.1016/j.canrad.2016.02.013. Epub 2016 Jun 20. Review. French.

PMID:
27340027
10.

[Small cell carcinoma of the prostate].

Alapont Alacreu JM, Montaner Ramírez MJ, Pontones Moreno JL, Valls Blasco F, Vera-Sempere FJ, Jiménez-Cruz JF.

Actas Urol Esp. 2002 Sep;26(8):585-8. Review. Spanish.

PMID:
12448178
11.

Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature.

Smith DC, Tucker JA, Trump DL.

J Clin Oncol. 1992 Mar;10(3):499-505. Review.

PMID:
1311029
12.

Neuroendocrine differentiation in human prostatic carcinoma.

di Sant'Agnese PA.

Hum Pathol. 1992 Mar;23(3):287-96. Review.

PMID:
1313390
13.

Aggressive variants of castration-resistant prostate cancer.

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA.

Clin Cancer Res. 2014 Jun 1;20(11):2846-50. doi: 10.1158/1078-0432.CCR-13-3309. Epub 2014 Apr 11. Review.

14.

Small-cell carcinoma of prostate.

Sarma DP, Weilbaecher TG.

Urology. 1989 Apr;33(4):332-5. Review.

PMID:
2538948
15.

Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.

Monn MF, Cheng L.

Expert Rev Anticancer Ther. 2016 Oct;16(10):1029-37. doi: 10.1080/14737140.2016.1226137. Epub 2016 Aug 26. Review.

PMID:
27534689
16.
17.

Small cell carcinoma of the prostate: molecular basis and clinical implications.

Wang L, Davidson DD, Montironi R, Lopez-Beltran A, Zhang S, Williamson SR, MacLennan GT, Wang C, Wang M, Emerson RE, Du X, Cheng L.

Histol Histopathol. 2015 Apr;30(4):413-24. doi: 10.14670/HH-30.413. Epub 2014 Nov 10. Review.

PMID:
25383744
18.

HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature.

Larnaudie L, Compérat E, Conort P, Varinot J.

Virchows Arch. 2017 Jul;471(1):133-136. doi: 10.1007/s00428-017-2134-y. Epub 2017 May 8. Review.

PMID:
28484843
19.

[Neuroendocrine prostate cancer].

Kretschmer A, Wittekind C, Stief CG, Gratzke C.

Urologe A. 2015 Dec;54(12):1779-83. doi: 10.1007/s00120-015-4015-9. Review. German.

PMID:
26582381
20.

Small cell carcinoma of the prostate.

Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA.

Nat Rev Urol. 2014 Apr;11(4):213-9. doi: 10.1038/nrurol.2014.21. Epub 2014 Feb 18. Review.

Supplemental Content

Support Center